Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: AVI Biopharma Inc. (AVII)

No earlier versions found for this Subject.

Return to AVI Biopharma Inc. (AVII)

AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology. Its principal products in development target life-threatening diseases, including cardiovascular disease, infectious disease, and cancer. AVI’s lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the re-narrowing of a coronary artery following angioplasty. In addition to targeting specific genes in the body, AVI’s antiviral program uses NEUGENE antisense compounds to combat disease by targeting single–stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease. The company has strategic alliances with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was incorporated in 1980 as Antivirals, Inc. and changed its name to AVI BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.